10429_infocus_parkinson_bw_17_tot

89. Worth PF. How to treat Parkinson’s disease in 2013. Clin Med. 2013;13:93-6.90. Yahr MD, Duvoisin RC, Schear MJ, et al. Treatment of parkinsonism with levodopa.Arch Neurol. 1969;21:343-54.91. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’sdisease: current controversies. Mov Disord. 2004;19:997-1005.92. Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62:1-8.93. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergicstimulation. Neurology. 2004;62:S47-55.94. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment ofParkinson’s disease: scientific rationale and clinical implications. Lancet Neurol.2006;5:677-87.95. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson’sdisease on quality of life and health-related costs: a prospective European study.Eur J Neurol. 2005;12:956-63.96. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. CurrMed Chem. 2004;11:2033-43.97. Müller T. Dopaminergic substitution in Parkinson’s disease. Expert OpinPharmacother. 2002;3:1393-1403.98. Todorova A, Chaudhuri RK. Subcutaneous apomorphine and non-motor symptomsin Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:1073-8.99. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in earlyParkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77:759-66.100. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesiaof severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:141-3.101. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease.Cochrane Database Syst Rev. 2003;(2):CD003467.102. Müller T. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionineand related mechanisms. Int Rev Neurobiol. 2010;95:49-71.103. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease.Mov Disord. 2009;24:541-50.104. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advancedParkinson’s disease: selection criteria and patient management. Expert RevNeurother. 2009;9:859-67.105. Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. NeuropsychiatrDis Treat. 2007;3:335-48.106. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment ofadvanced Parkinson’s disease. Curr Med Res Opin. 2011;27:907-19.107. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel inadvanced Parkinson’s disease open-label study: interim results. ParkinsonismRelat Disord. 2013;19:339-45.80 InFocus Niet-motorische verschijnselen bij de ziekte van Parkinson